<table className="table">
  <caption><p>
    Features of ANCA-Associated Vasculitis</p>
  </caption>
  <thead>
    <tr>
      <th rowSpan="1" colSpan="1"><p>
        Feature</p>
      </th>
      <th rowSpan="1" colSpan="1"><p>
        Granulomatosis With Polyangiitis</p>
      </th>
      <th rowSpan="1" colSpan="1"><p>
        Microscopic Polyangiitis</p>
      </th>
      <th rowSpan="1" colSpan="1"><p>
        Eosinophilic Granulomatosis With Polyangiitis</p>
      </th>
    </tr>
  </thead>
  <tbody>
    <tr className="group_1-1 row-odd">
      <td rowSpan="1" colSpan="1"><p>
        ANCA</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        c-ANCA (antiproteinase-3 antibodies) (&gt;95%)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        p-ANCA (antimyeloperoxidase antibodies) (50%-75%)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        p-ANCA (antimyeloperoxidase antibodies) (~50%)</p>
      </td>
    </tr>
    <tr className="group_1-2 row-even">
      <td rowSpan="1" colSpan="1"><p>
        Vascular histology</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Pauci-immune necrotizing granulomatous vasculitis</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Pauci-immune nongranulomatous necrotizing vasculitis</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Pauci-immune necrotizing granulomatous vasculitis with eosinophilic infiltration of vessel walls and tissues; extravascular granulomas</p>
      </td>
    </tr>
    <tr className="group_1-3 row-odd">
      <td rowSpan="1" colSpan="1"><p>
        Cardiac</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Pericarditis; myocarditis; conduction disorder (&lt;10%)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        —</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Pericarditis; myocarditis; conduction disorder; heart failure (27%-47%)</p>
      </td>
    </tr>
    <tr className="group_1-4 row-even">
      <td rowSpan="1" colSpan="1"><p>
        Ears/nose/throat</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Crusting; rhinorrhea; sinusitis; otitis media; chondritis of ears and nose with saddle nose deformity; septal perforation (70%-100%)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Sinusitis; sensorineural hearing loss (9%-30%)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Nasal polyps; rhinitis; sinusitis (prodromal)</p>
      </td>
    </tr>
    <tr className="group_1-5 row-odd">
      <td rowSpan="1" colSpan="1"><p>
        Gastrointestinal</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Ulceration; perforation (5%-11%)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Abdominal pain; bleeding (30%-58%)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Abdominal pain; bleeding</p>
      </td>
    </tr>
    <tr className="group_1-6 row-even">
      <td rowSpan="1" colSpan="1"><p>
        Kidney</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Pauci-immune necrotizing glomerulonephritis (40%-100%)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Pauci-immune necrotizing glomerulonephritis (80%-100%)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Pauci-immune necrotizing glomerulonephritis (25%)</p>
      </td>
    </tr>
    <tr className="group_1-7 row-odd">
      <td rowSpan="1" colSpan="1"><p>
        Lung</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Alveolar hemorrhage; nodules (50%-90%); tracheal/subglottic stenosis (10%-15%)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Alveolar hemorrhage; pulmonary infiltrates; pulmonary fibrosis (25%-55%)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Asthma (prodromal, &gt;90%); nodular opacities; infiltrates (25%-86%)</p>
      </td>
    </tr>
    <tr className="group_1-8 row-even">
      <td rowSpan="1" colSpan="1"><p>
        Ocular</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Scleritis; episcleritis; retinal vasculitis; retro-orbital pseudotumor; dacryoadenitis (14%-60%)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        —</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        —</p>
      </td>
    </tr>
    <tr className="group_1-9 row-odd">
      <td rowSpan="1" colSpan="1"><p>
        Neurologic</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Mononeuritis multiplex, sensorimotor peripheral neuropathy (33%)</p><p>
        Central nervous system involvement (pachymeningitis) (&lt;5%)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Distal symmetric polyneuropathy; mononeuritis multiplex (37%-72%)</p><p>
        Central nervous system pachymeningitis; cerebral hemorrhage; infarcts (&lt;20%)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Sensorimotor peripheral neuropathy, mononeuritis multiplex (≤75%)</p>
      </td>
    </tr>
    <tr className="group_1-10 row-even">
      <td rowSpan="1" colSpan="1"><p>
        Skin</p>
      </td>
      <td rowSpan="1" colSpan="3"><p>
        Petechiae/purpura; painful skin lesions; maculopapular rash; livedo reticularis; ulcers</p>
      </td>
    </tr>
  </tbody>
</table>